EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Pharmacokinetics, Bioequivalence, and Safety Evaluation of 2 Formulations of 10‐mg Rivaroxaban Tablets: A 4‐Period Crossover Trial

Canhua Zhang, Zihan Shen, Jianhao Li, Yaofen Wu, Zuoheng Xu, Wenzhao Gu, Jianqing Jian, Zixing Wu, Weixiong Liu, Hui Yang, Jianfen Su

Clinical Pharmacology in Drug Development · 2023

DOI: 10.1002/cpdd.1261 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2023. Verfasst von Canhua Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou Panyu Central Hospital, Guangzhou, China. Hauptthemen laut MEDLINE: Rivaroxaban, Factor Xa Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Guangzhou Municipal Science and Technology Bureau, Guangzhou Panyu Central Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study compared the safety, bioequivalence, and pharmacokinetic properties of 2 formulations of 10‐mg rivaroxaban tablets in healthy Chinese participants in fasting and fed arms. The trial was an open, randomized, 4‐period, replicated crossover scheme, and 36 volunteers were recruited separately for the fasting and fed arms. Volunteers were randomly administered a single dose of the test or reference formulation (10 mg) orally, followed by a 5‐day washout period. Rivaroxaban concentrations in the plasma were determined using liquid chromatography–tandem mass spectrometry, and pharmacokinetic parameters were obtained from the concentration‐time profiles. The mean values of the test and the reference product for the area under the plasma concentration–time curve from time 0 to the last measurable concentration, area under the plasma concentration–time curve from time 0 to infinity, and maximum plasma concentration were 996 and 1014 ng • h/mL, 1024 and 1055 ng • h/mL, and 150 and 152 ng/mL in the fasting arm, respectively; the values were 1155 and 1167 ng • h/mL, 1160 and 1172 ng • h/mL, and 202 and 193 ng/mL in the fed arm, respectively. All the parameters were within acceptable limits in terms of bioequivalence. No serious adverse events were observed. This study demonstrated that the 2 rivaroxaban tablets were bioequivalent in healthy Chinese participants under fasting and fed conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanFactor Xa InhibitorsHumansTherapeutic EquivalencyCross-Over StudiesMaleAdultTabletsYoung AdultFemaleFastingArea Under CurveHealthy VolunteersAdministration, OralTandem Mass SpectrometryChromatography, LiquidDrug Compounding

Stichwörter der Autor:innen

bioequivalencehealthy Chinese volunteerspharmacokineticsrivaroxabansafety

Substanzen

RivaroxabanTabletsFactor Xa Inhibitors

Autor:innen und Institutionen

  • Guangzhou Panyu Central Hospital, Guangzhou, China.
  • School of Pharmacy, Guangdong Medical University, Dongguan, China.
  • The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China.
  • College of Pharmacy, Jinan University, Guangzhou, China.
  • Cardiovascular Institute of Panyu, Guangzhou, China.

Förderung

  • Guangzhou Municipal Science and Technology Bureau
  • Guangzhou Panyu Central Hospital

Zitieren

APA

Zhang, C., Shen, Z., Li, J., Wu, Y., Xu, Z., Gu, W., Jian, J., Wu, Z., Liu, W., Yang, H., & Su, J. (2023). Pharmacokinetics, Bioequivalence, and Safety Evaluation of 2 Formulations of 10‐mg Rivaroxaban Tablets: A 4‐Period Crossover Trial. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1261

Vancouver

Zhang C, Shen Z, Li J, Wu Y, Xu Z, Gu W, et al. Pharmacokinetics, Bioequivalence, and Safety Evaluation of 2 Formulations of 10‐mg Rivaroxaban Tablets: A 4‐Period Crossover Trial. Clinical Pharmacology in Drug Development. 2023. doi:10.1002/cpdd.1261

BibTeX
@article{Zhang2023,
  author = {Zhang, Canhua and Shen, Zihan and Li, Jianhao and Wu, Yaofen and Xu, Zuoheng and Gu, Wenzhao and Jian, Jianqing and Wu, Zixing and Liu, Weixiong and Yang, Hui and Su, Jianfen},
  title = {Pharmacokinetics, Bioequivalence, and Safety Evaluation of 2 Formulations of 10‐mg Rivaroxaban Tablets: A 4‐Period Crossover Trial},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2023},
  doi = {10.1002/cpdd.1261}
}
Kostenlos starten →